Literature DB >> 27919789

Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness.

Sotiris Galtsidis1, Stella Logotheti1, Athanasia Pavlopoulou2, Christos P Zampetidis3, Georgia Papachristopoulou4, Andreas Scorilas4, Borek Vojtesek5, Vassilis Gorgoulis3, Vassilis Zoumpourlis6.   

Abstract

The transcription factor p73 is homologous to the well-known tumor-suppressor p53. The p73-regulated networks are of significant clinical interest, because they may substitute for impaired p53-regulated networks which are commonly perturbed in cancer. Herein, we aimed to characterize a p73-regulated network that mediates cell migration and restores anti-oncogenic responses in p53-mutant cancer cells. In this study, we demonstrate that p73 regulates a network underlying cell migration, which consists of MIR34A/MIR3158/vimentin/β-catenin/lef1. The p73 isoforms transactivate the miRNA components (MIR34A/MIR3158) of this network, which in turn, downregulate their EMT-related mRNA co-targets (vimentin/β-catenin/lef1) to decrease cell-migration. Modulation of this network, by increasing the level of the novel p73-dependent target MIR3158, was found to induce anti-oncogenic/anti-invasive responses in p53-mutant cancer cells. Taken together, a p73-regulated, MIR3158-containing, network restores anti-invasive phenotypes in p53-mutant cancer cells; this property could be exploited towards the development of anticancer therapeutics.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer targeting; Epithelial–mesenchymal transition; MIR3158; MIR34A; p73

Mesh:

Substances:

Year:  2016        PMID: 27919789     DOI: 10.1016/j.canlet.2016.11.036

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  Pan-sarcoma characterization of lncRNAs in the crosstalk of EMT and tumour immunity identifies distinct clinical outcomes and potential implications for immunotherapy.

Authors:  Deyao Shi; Shidai Mu; Feifei Pu; Binlong Zhong; Binwu Hu; Muradil Muhtar; Wei Tong; Zengwu Shao; Zhicai Zhang; Jianxiang Liu
Journal:  Cell Mol Life Sci       Date:  2022-07-16       Impact factor: 9.207

Review 3.  p73 isoforms meet evolution of metastasis.

Authors:  Stella Logotheti; Athanasia Pavlopoulou; Stephan Marquardt; Işıl Takan; Alexandros G Georgakilas; Thorsten Stiewe
Journal:  Cancer Metastasis Rev       Date:  2022-08-11       Impact factor: 9.237

Review 4.  The comprehensive landscape of miR-34a in cancer research.

Authors:  Sijing Li; Xiaohui Wei; Jinyong He; Quanquan Cao; Danyu Du; Xiaoman Zhan; Yuqi Zeng; Shengtao Yuan; Li Sun
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

5.  MiR-1180-5p regulates apoptosis of Wilms' tumor by targeting p73.

Authors:  Xiuyun Jiang; Huaicheng Li
Journal:  Onco Targets Ther       Date:  2018-02-16       Impact factor: 4.147

Review 6.  p53-Related Transcription Targets of TAp73 in Cancer Cells-Bona Fide or Distorted Reality?

Authors:  Chao Wang; Cui Rong Teo; Kanaga Sabapathy
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 5.923

Review 7.  The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer.

Authors:  Callum Hall; Patricia A J Muller
Journal:  Int J Mol Sci       Date:  2019-12-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.